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Targeting choroid plexus epithelia and
ventricular ependyma for drug delivery
to the central nervous system
Ana Maria Gonzalez1, Wendy E Leadbeater1, Michael Burg2, Karen Sims1, Tetsuya Terasaki3, Conrad E Johanson4,
Edward G Stopa4, Brian P Eliceiri2, Andrew Baird1,2*
Abstract
Background: Because the choroid plexus (CP) is uniquely suited to control the composition of cerebrospinal fluid
(CSF), there may be therapeutic benefits to increasing the levels of biologically active proteins in CSF to modulate
central nervous system (CNS) functions. To this end, we sought to identify peptides capable of ligand-mediated
targeting to CP epithelial cells reasoning that they could be exploited to deliver drugs, biotherapeutics and genes
to the CNS.
Methods: A peptide library displayed on M13 bacteriophage was screened for ligands capable of internalizing into
CP epithelial cells by incubating phage with CP explants for 2 hours at 37C and recovering particles with targeting
capacity.
Results: Three peptides, identified after four rounds of screening, were analyzed for specific and dose dependant
binding and internalization. Binding was deemed specific because internalization was prevented by co-incubation
with cognate synthetic peptides. Furthermore, after i.c.v. injection into rat brains, each peptide was found to target
phage to epithelial cells in CP and to ependyma lining the ventricles.
Conclusion: These data demonstrate that ligand-mediated targeting can be used as a strategy for drug delivery to
the central nervous system and opens the possibility of using the choroid plexus as a portal of entry into the brain.
Background
Of the many strategies to defeat and bypass the blood
brain barrier (BBB) for the purposes of drug delivery
[1,2], the unique biological and biophysical features of
the choroid plexus (CP), its intrinsic ability to produce
cerebrospinal fluid (CSF) and its capacity to place bioac-
tive proteins into CSF [3-11] have largely been ignored.
More recently, there are a number of reports suggesting
the possibility that secretory epithelial cells of the CP
present a potential window into the central nervous sys-
tem (CNS) for the purposes of drug delivery [5,9,12-14].
On one hand, if CP-epithelial drug targeting strategies
could be developed and validated, then drugs, proteins
and gene based medicines might be delivered to the CP
for their translocation into CSF and availability to brain
parenchyma. Alternatively, drug-targeting to the CP
epithelial cells could be used to alter unique functions
of CP epithelial cells that include CSF production and
the transport in, and out, of the CNS of critical compo-
nents like ions, vitamins, hormones and proteins like
ascorbic acid, amyloid beta protein [5].
In as much as CSF-producing CP epithelia are distinct
cellular structures within the CNS and anatomically
accessible via a fenestrated endothelium, we wondered
whether phage display might be used to identify target-
ing ligands capable of delivering drugs into CP epithelial
cells. As a first step towards this goal, our previous stu-
dies identified epidermal growth factor (EGF) as a
potential ligand capable of mediating particle internali-
zation into target cells [15-19] and we showed its ability
to enter CP epithelia in vitro and transduce them
in vivo [20]. Like the receptors for adenoviral and
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lentiviral gene delivery vectors which can also transduce
choroid epithelial cells after i.c.v. injection [21,22], the
EGF receptor is widely distributed. Moreover, the ligand,
EGF, has intrinsic epidermal cell growth promoting bio-
logical activity [23,24] that significantly limits its utility
as a drug- and particle-targeting agent.
In this study, we attempted to validate an approach
that might increase CP targeting specificity. To this end,
we show that a combinatorial peptide library containing
over 109 different peptides can be selectively mined for
ligands that allow binding and internalization into
mouse CP explants. Three ligand-targeting phage recov-
ered by biopanning have the capacity to target and
internalize particles into CP epithelial cells in culture
using TCSFB cells. Furthermore, after i.c.v. injection
into lateral ventricles, the targeted phage internalize into
CP epithelial cells and ependyma cells. Because the tar-
geted binding is specific and dose dependent, the possi-
bility arises that these targeted phage may be candidates
to re-engineer CNS gene delivery vectors and drug tar-
geting to the CNS.
Results
Biopanning PhD-C7C libraries of phage for peptides
internalizing into CP Explants
As shown in Table 1, three recovered peptides named
“Peptide B” (R3P3.9), “Peptide C” (R4P4.5) and “Peptide
D” (R4P4.7) were selected from the 25 unique sequences
obtained for further analysis from 3-4 rounds of biopan-
ning on explants of 4th ventricle mouse choroid plexus.
A 5th round of biopanning did not provide further
enrichment of library collapse and was not studied.
Freshly dissected choroid plexus were incubated with the
1 × 1011 phage for 2 hours as indicated in Materials and
Methods, unbound phage washed off and any phage par-
ticles that had not washed off were presumed to be inter-
nalized and were recovered by phage display biopanning
[16,25]. No sequencing was performed after the first and
second rounds of biopanning but of the 19 sequences
obtained after Round 3, the data suggested that the origi-
nal library had collapsed to 5 families of sequences of
which 3 peptides (R3P3.9, R3P3.23 and R3P3.24) were
identical. Representing the Family 1 of sequences, the
candidate (CHGNHMPAC) was called “Peptide B”. On
the 4th round of screening, this peptide B sequence
(R3P3.9) was not recovered but a peptide identified in
Round 3 (R3P18) and representing Family 4 sequences
like R3P18, R3P6, R3P3.12 and R3P3.10 detected in
Round 3 was identified in Round 4 (R4P15). As such this
sequence (CSASTHKAC) was selected for further evalua-
tion and called “Peptide C”. A 2nd identical member of
this 4th family was detected in both Rounds 3 (R3P3.6)
and 4 (R4P4.7) and this peptide (CTSTSYKMC) was
called Peptide D. Wild type phage with no peptide insert
was called “Peptide A” and each particle tested blind for
binding and internalization.
Table 1 Identification of CP-targeting peptides
Clone Sequence Family Repeat Clone Sequence Family Repeat
3.1 CHERPSSLC 3 4.2 CKALDATTC 4
3.2 CPAVVRGSC 5 4.5 CSASTHKAC 4
3.3 CDHRSSAQC 3 4.7 CTSTSYKMC 5 3.6/4.15
3.5 CLRSQGPVC 1 4.8 CTKMHLPQC 6
3.6 CTSTSYKMC 4 4.7 4.11 CAPHSTSAC 5
3.7 CQPTHSQSC 2 4.12 CHHPQNRHC 6
3.8 CSMPHLTSC 5 4.15 CSASTHKAC 4 3.18/4.5
3.9 CHGNHMPAC 1 3.23/3.24 4.16 CHGPIDKSC 6
3.10 CKSIPTNAC 4 4.19 CIPTSIRHC 5
3.12 CMSGKHLKC 4 4.23 CSPKGSHSC 5
3.15 CLRDDSHSC 1
3.16 CHHQHSPQC 1
3.17 CEWPTSSTC 3
3.18 CSASTHKAC 4 4.15
3.19 CNSHASPHC 1
3.21 CIIGQGPSC 1
3.22 CMMPSRSLC 5
3.23 CHGNHMPAC 1 3.24/3.9
3.24 CHGNHMPAC 1 3.23/3.9
Peptide sequences obtained from after 3 and 4 rounds of biopanning were compared, assigned to one of six different families of sequences and repeat
recoveries noted as described in the text.
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Targeted peptide phage are internalized by cells in
CP explants
We used immunohistochemistry to evaluate whether the
particles identified by biopanning internalized into CP
explants and behaved as predicted (Figure 1). Mouse CP
were dissected from either the lateral or 4th ventricle as
described in Material and Methods and incubated
with the untargeted phage A or the peptide targeted B-,
C- or D-particles at a concentration of 1 × 1011pfu/ml
for 2 h at 37C. To remove any particles that might be
non specifically bound to the cell surface, the explants
were washed with PBS containing Tween-20, fixed in
methanol and then immuno-stained with antibodies
against M13 phage as described in Materials and Meth-
ods. Binding of primary antibodies was detected
using Alexa594-goat anti-rabbit antibodies. As shown in
Figure 1, little immunostaining is observed when chor-
oid plexus explants are incubated with Peptide-A (untar-
geted) control phage (Panel A). In contrast,
immunoreactive M13 staining is observed in the cyto-
plasm of what appears to be selected populations of
epithelial cells after incubation with particles targeted
with Peptide-B (Panel B), Peptide-C (Panel C) or Pep-
tide-D (Panel D) targeted phage indicating the internali-
zation of these targeted particles by epithelial cells in
the choroid plexus. We noted regional differences in the
internalization and distribution of targeted cells in the
explants with each targeted phage. While we consis-
tently observed non-uniform internalization, it was not
possible to determine whether this pattern represented
restricted availability of particles to the explants or the
existence of unique cell specific distributions of targeted
receptors.
Peptide-targeting is specific
As also shown in Figure 1, CP explants were treated
with either media (Panel A), 200 ng/ml of synthetic Pep-
tide C (Panel E) or 200 ng/ml of Peptide-D (Panel F) in
addition to either 1 × 1011pfu/ml of Peptide-C targeted
phage (Panels A&C) or 1 × 1011pfu/ml of Peptide-D tar-
geted phage (Panels B&D) for 2 h at 37C. Prior to stain-
ing, cells were washed with 50 mM Glycine, pH 2.8,
fixed and immunostained with antibodies against M13
phage. Binding of primary antibodies was detected using
Alexa594-goat anti rabbit antibodies. After 2 h, intense
intracellular immunoreactivity was observed in cells
incubated with PhD C targeted phage (Panel C) or Pep-
tide-D targeted phage (Panel D). When explants were
pretreated with either Peptide-C (Panel E) or Peptide-D
(Panel F), no specific staining was observed in the
explants indicating that the internalization of the Pep-
tide-C and Peptide-D targeted phage was displaced by
the excess peptide.
Internalization of PhD-targeted peptide phage in CP cells
in vitro
To confirm epithelial cell targeting and to determine
whether there existed specificity for epithelial cell subpo-
pulations, rat choroid plexus epithelial cells from the TR-
CSFB cell line were incubated with Peptide-A (control),
Peptide-B, Peptide-C or Peptide-D targeted phage (5 ×
1010pfu/ml) for 2 h at 37C, then acid washed to remove
any particles on the cell surface, fixed and immunos-
tained with antibodies against M13 phage (Figure 2).
Binding of primary antibodies was detected using
Alexa594-goat anti rabbit antibodies. No internalization is
observed when the cells are treated with control PhD A
phage (Panel A). Significant intracellular immunoreactiv-
ity is observed in TR-CSFB cells after incubation with
PhD B (Panel B), PhD C (Panel C) or PhD D (Panel D).
M13 phage, red; Cell nuclei (DAPI), white. The TR-CSFB
cells were also co-incubated with excess of free Peptide-C
(Panel E) or Peptide-D (Panel F) and cells were washed
with 50 mM Glycine, pH 2.8, fixed and then immunos-
tained with antibodies against M13 phage. In both
instances, internalization is almost completely blocked
when the targeted particles are competing for binding to
cell surface receptors with an excess of ligand.
Internalization of PhD targeted-phage is dose and
time dependant
To evaluate the binding kinetics of phage internalization,
TR-CSFB cells were incubated with increasing concentra-
tions of Peptide-D-targeted phage for 2 h, at 37C
(Figure 3). Cells were acid washed to remove cell surface
binding, immunostained with antibodies against M13
phage and detected using Alexa594 goat labeled anti-rabbit
antibodies. At 1 × 109 pfu/ml, little significant intracellular
staining is observed (Panel A) but at 1 × 1010 pfu/ml
(Panel B) there is detectable immunoreactivity for M13 in
the cytoplasm which clearly increases when the cells are
incubated with 1 × 1011 pfu/ml (Panel C). This experiment
shows that there is a clear dose dependant correlation
between phage titer and intensity of intracellular immu-
noreactivity. Similarly, if TR-CSFB cells were incubated
with Peptide-D targeted phage (5 × 1010pfu/ml) and acid
washed, immunostained and visualized analyzed at differ-
ent times, by 15 min, Peptide-D-targeted phage are already
internalized (Panel D) and the intracellular staining
increases by 2 h (Panel E). By 48 h (Panel F), there is a
reduction on the amount of immunoreactive M13 which
by 72 his negligible non detectable (not shown).
Targeted phage are internalized by choroid epithelial
cells and ventricular epithelial cells after ICV injection
In Figure 4, control Peptide-A (Panel A) or targeted
Peptide-B (Panel B), Peptide-C (Panel C) or Peptide-D
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Figure 1 Targeted-phage internalize into cells in CP explants in a ligand dependant fashion. Choroid plexus was dissected from the
lateral and 4th ventricle and incubated with PhD-targeted phage (1 × 1012pfu/ml) for 2 h at 37C. To remove any particles bound to the cell
surface, the explants were washed with PBS containing Tween 20, fixed and then immunostained with antibodies against M13 phage. Binding of
primary antibodies was detected using Alexa594-goat anti rabbit antibodies. No immunostaining was observed when choroid plexus explants
were incubated with Peptide A control phage (Panel A). In contrast, immunoreactive M13 staining was observed in the cytoplasm of selected
populations of epithelial cells after incubation with Peptide B (Panel B), Peptide C (Panel C) or Peptide D (Panel D) targeted phage indicating the
internalization of these targeted particles by epithelial cells in the choroid plexus. To demonstrate that internalization is ligand-mediated,
explants were co-incubated with 200 ng/ml Peptide C (Panel E) or Peptide D (Panel F) and the targeted phage. M13 phage: red; Cell nuclei
(DAPI): white.
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Figure 2 Internalization and specificity of PhD-targeted peptide phage in CP cells in culture. TR-CSFB cells were incubated with
untargeted or targeted phage (5 × 1010pfu/ml) for 2 h at 37C, acid washed to remove any particles on the cell surface, fixed and then
immunostained with antibodies against M13 phage and subsequently Alexa594-labeled goat anti rabbit antibodies. Little internalization is
observed when the cells were treated with control phage (Panel A) and while cells tended to clump together upon staining, significant
intracellular immunoreactivity was nevertheless observed in TR-CSFB cells after incubation with Peptide B (Panel B), Peptide C (Panel C) or
Peptide D (Panel D) targeting of phage. M13 phage: red; Cell nuclei (DAPI): white. To demonstrate that internalization was ligand-mediated, TR-
CSFB cells were incubated with targeted phage (1 × 1010pfu/ml) for 2 h at 37C in the absence (Panel A) or presence of an excess (200 ng) of
Peptide C (Panel E) or Peptide D (Panel F). M13 phage: red; Cell nuclei (DAPI): white.
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(Panel D) phage were injected into the lateral ventricle
of rats and 24 h later brains were collected and 10 um
sections immuno stained with anti-M13 antibodies. Very
low immunoreactivity was observed in the choroid
plexus after wild type phage injection (Panel A). How-
ever, after P Peptide-B (Panel B), Peptide-C (Panel C) or
Peptide-D (Panels D) targeted phage injections, strong
M13 immunoreactivity was observed within most of the
epithelial cells of the choroid plexus. Little staining is
detected in brain parenchyma although non-specific tar-
geting was detected at the level of the arachnoid mem-
branes (not shown). Very low immunoreactivity was
observed in the ependymal cells after control phage
injections (Panel E) but after Peptide-B targeted phage
injections selected populations of ependymal cells were
strongly stained for M13. (Panel F). After Peptide-C tar-
geted and Peptide-D targeted phage i.c.v. injections,
ependymal cells of the lateral ventricle clearly show
intracellular and uniform immunostaining (Panel G and
Panel H).
Discussion
We selected three peptides to show that it is possible to
identify drug-targeting candidates for CNS drug delivery
from a phage peptide library. Our biopanning strategy
for targeting generated over two dozen new sequences
that we predicted would be biased for luminal targeting
of CP epithelial cells because the screen used CP
explants freshly dissected from donor mice. The three
peptides were selected because they were found to have
either increased representation in the limited number of
clones sequenced (e.g. R3.9) or alternatively whose
sequences appeared after 3rd and 4th rounds of biopan-
ning. These peptides, along with EGF [20], are proven
Figure 3 Internalization of PhD targeted-phage is dose dependant in CP cells in vitro. TR-CSFB cells were incubated with increasing
concentrations of Peptide D-targeted phage for 2 h, at 37C. Cells were acid washed to remove cell surface binding, immunostained with
antibodies against M13 phage and subsequently detected using Alexa594-labeled goat anti-rabbit antibodies. At 1 × 109 pfu/ml, no significant
intracellular staining was observed (Panel A). At 1 × 1010 pfu/ml (Panel B), there was detectable immunoreactivity for M13 in the cytoplasm
which clearly increased when the cells were incubated with 1 × 1011 pfu/ml (Panel C). This experiment shows that there was a correlation
between phage titer and the intensity of intracellular immunoreactivity indicating that internalization is dose dependant. Internalization of
targeted-phage was also time-dependant (Panels D-E). TR-CSFB cells were incubated with Peptide D-targeted phage (5 × 1010pfu/ml) at 37C,
acid washed, immunostained with M13 antibodies and internalization visualized using Alexa594 labeled secondary antibodies. Cells were
counterstained with DAPI to visualize the cell nuclei. By 15 min, Peptide D-targeted phage were already internalized (Panel D) and this
intracellular staining increases over the following 2 h (Panel E) but particle is degraded by 48 h (Panel F). M13 phage: Red; Cell nuclei: white.
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capable of targeting CP epithelial cells in vitro, ex vivo
and in vivo. Whether they can target cells for transduc-
tion after i.c.v. injection like EGF [20] remains to be
established.
In 1985, Smith [26] conceived of phage display as a
method whereby short nucleic acid sequences of DNA
could be inserted into the coding sequence of the M13
phage glll gene to generate particles that display on
their capsid surface a peptide-plll fusion protein. Rea-
soning that the displayed peptides would confer phage
with new intrinsic activities, he proposed that it should
be possible to introduce random and known sequences
of DNA into the glll gene to create particles with new
activities. Over the last twenty years, we and other
investigators have been adapting this original phage dis-
play technique to identify novel peptides with different
specificities and activities (reviewed in [27,28]), for
example, peptides have that confer physical stability to
particles in organic solvents like chloroform, decrease
complement activation of macromolecules in blood,
modify immunogenicity, alter viral tropism in vitro and
in vivo, internalize particles and transduce cells, promote
transcytosis in vitro and in vivo and even promote trans-
migration of particles across cell barriers in vitro and
in vivo [29-53].
Our laboratories’ focus has been to identify and
exploit ligands that internalize into target cells with a
long-term objective of improving the specificity of drug,
protein and gene-based medicine delivery. To this end,
we have re-engineered phage vectors for increased bind-
ing to mammalian cells and monitored their entry into
cells by immunohistochemistry for internalization drug
delivery, transfection for nucleotide delivery and trans-
duction for gene expression [15-19,25,54-58]. It seemed
reasonable to propose that these methods might
deployed towards CNS drug delivery because ligands
like EGF can target the phage particle to cells [20].
Several years ago, investigators [14] proposed that it
might be possible to target therapeutics to the CNS by
exploiting one of the unique features of the choroid
plexus: it exists at the interface between blood and CSF.
If possible, drugs could then be designed to act like
ascorbic acid and translocate across the CP epithelium
for entry into CSF and access to brain parenchyma
[59-61]. Alternatively, drugs could be targeted to the CP
epithelium so as to modify its hydrodynamic and
homeostatic functions in controlling CSF production
and composition respectively. We show here that when
phage are re-engineered so that they can target the
choroid plexus epithelium, they internalize into epithe-
lial cells when tested in vitro, ex vivo and in vivo. The
targeting is ligand specific, concentration and time
dependant.
The possibility of exploiting epithelial routes of drug
delivery to the CNS is not new. For example, we origin-
ally proved the concept of CP targeting with the ligand
Figure 4 Peptide-targeted phage are internalized by choroid epithelial cells and ependyma 24 h after icv injection. Control phage
(Panel A), Peptide B (Panel B), Peptide C (Panel C) or Peptide D (Panel D) -targeted phage (1 × 1011/10 ul) were injected into the lateral
ventricle of anesthetized rats and 24 h later brain were collected and frozen sections immunostained with anti-M13 antibodies. Whereas low
background immunoreactivity was observed in choroid plexus epithelial cells after control (untargeted) phage injections (Panel A), Peptide B
(Panel B), Peptide C (Panel C) and Peptide D (Panel D) -targeted phage injections resulted in strong M13 immunoreactivity was observed within
most of the epithelial cells of the choroid plexus. Similarly, very low immunoreactivity was observed in the ependymal cells after a wild type
phage injection (Panel E) but after Peptide B (Panel F), Peptide C (Panel G) and Peptide D (Panel H) targeting, ependymal cells of the lateral
ventricle clearly show intracellular immunostaining. Notice the lack of M13 immunoreactivity observed in the brain parenchyma in all treatments.
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EGF [20] but it was clear from the outset that this
ligand is not ideally suited for CP targeting. First, EGF
has intrinsic activity and is a naturally occurring growth
factor. Second, while EGF may be selective for epithelial
cells in the brain as described here, but there are several
alternative cell types that express EGF receptors includ-
ing astrocytes, activated glia and endothelial cells. The
specificity that we observe with i.c.v. injections is likely
due to the compartmentalization of phage in the ventri-
cular space and the limited number of cell types avail-
able for targeting. Herenu et [62] also explored the
ependymal route for insulin like growth factor-1 (IGF-1)
gene delivery in an attempt to circumvent the need to
transport IGF-1 from blood into brain by injecting pep-
tide i.c.v. [63,64]. In this case, they exploited adenoviral
selectivity to infect epithelial cells when injected i.c.v. to
increase the levels of IGF1 in CSF and mimic the con-
centrations achieved by the injection of protein into
CSF. Presumably, adenoviral-retargeting strategies that
modify its pharmacokinetics, biological activity and even
potency could be used to improve its use as a gene
delivery agent to the CNS.
In the study described here, we have not studied the
mechanism of internalization or the specific trafficking
of the particles once they enter the cell. The fact that
the peptide ligand can prevent internalization suggests
specificity for cell binding. The observation that the par-
ticles are internalized in a ligand dependant fashion sup-
ports the hypothesis that phage bind to cells via cognate
receptors to the peptides displayed. The identity of
these receptors remains unknown but clearly phage dis-
play should be considered as a viable method to identify
novel portals of entry into the CNS via delivery to CPe
cells.
Using the CP as a doorway into the CNS has also
gained momentum with significant difficulties in over-
coming the blood brain barrier [1,65,66]. Just as there
are reports that propose using brain’s endothelium as a
target for CNS drug delivery using molecular signatures
[44,46,48] in brain endothelia, Chen et al [67] showed
that CNS-directed enzyme therapy was feasible by tar-
geting epitope-modified adeno-associated virus. While
the effects are certainly local, the wide distribution of
endothelium in the CNS would ensure wide distribution
of drug throughout the brain, if all endothelia were tar-
geted. For similar reasons, there is considerable interest
in targeting the choroid epithelium [5,59]. First, the
design and structure of barriers are not homogenous
throughout the brain and areas like the arcuate nucleus
are open to CSF while others, like median eminence, are
open to the portal blood [68]. Second, the choroid
plexus is actively modulating CSF content and composi-
tion in response to the environment [69] which regulate
brain state and neuroactive peptide distribution in CSF
[10]. Third, the choroid plexus can play a prominent
role in neuroprotection [9] because of special axonal
endings that are formed at CSF contacting neurons
[70-72] which presumably enable communication
between brain parenchymal cells and CSF. Finally, epen-
dymal cells, which divide asymmetrically and transfer
progeny into the subventricular zone activated by injury
[73] are in direct contact with CSF and CP produced
neuroactive agents in CSF. In as much as this subepen-
dymal zone is a neurogenic niche [74] that is influenced
by CP epithelial cells and an ependymal layer controlling
of CSF hydrodynamics and content, these cells are
nearly ideally localized to modulate CNS functions and
treat brain disease if they can be targeted to produce
therapeutics. As demonstrated by Regev et al [75], lenti-
viral transduction of choroid plexus epithelium with
genes encoding neuroactive peptides can control
CNS function thereby supporting the feasibility of
CP-mediated drug delivery.
Conclusions
It is interesting to speculate that while our results sup-
port the feasibility of targeted delivery to choroid plexus
epithelia and ependyma after i.c.v. injection of re-
engineered particles, a more innovative therapeutic
deployment would ideally involve exploiting epitopes on
the basolateral epithelium that would allow targeting of
particles from blood, through stroma and to the CP
epithelial barrier. To this end, in vivo biopanning of
basolateral CP epithelia at their stromal-endothelial
interface using phage display libraries could be devel-
oped using homing techniques originally developed for
vascular targeting described above [46]. Inasmuch as
these approaches have already proven useful for target-
ing brain endothelia to modify their function [67], a
similar strategy could be used to identify peptides cap-
able of homing particles for drug transport to CP and
translocation into CSF.
Methods
Peptide library and biopanning
All of the experiments described here used the con-
strained PHD-C7C library from New England Biolabs
(Ipswitch, MA) that consisted of a disulfide-constrained
heptapeptide (PHD-C7C). The randomized peptide seg-
ment is flanked by a pair of cysteine residues, which
results in the display peptide loops rather than linear
sequences. All of the libraries have reported complex-
ities in excess of 2 × 109 independent clones and are
displayed at the N-terminus of the minor coat protein
pIII on M13 phage at a valency of 5 peptides per virion.
The first randomized position in the PHDC7C library is
preceded by Ala-Cys and all of the libraries contain a
short linker sequence (Gly-Gly-Gly-Ser) between the
Gonzalez et al. BMC Neuroscience 2011, 12:4
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displayed peptide and pIII. For screening libraries, we
deployed a binding and internalization strategy to iden-
tify peptides capable of interacting with mouse CP
explants that were dissected as described below. Tissue
was incubated with libraries in DMEM culture media
supplemented with 10% calf serum in tissue culture
plates for 2 hours at 37C in an atmosphere of 95% CO2
to allow for binding and internalization. At the end of
the incubation period, the explants were carefully
removed from the incubation media, placed into eppen-
dorf tubes containing extraction-lysis buffer and pro-
cessed according to the manufacturers (New England
Biolabs) recommendations. Phage were recovered,
amplified by infection of host bacteria and, after purifi-
cation by PEG precipitation, the selection repeated over
four more rounds until the library had collapsed and
families of related peptide sequences could be identified.
For all testing on cells, endotoxin was removed byTri-
tonX-114 phase separation[76] to eliminate non-specific
internalization that accompanies LPS contamination
(unpublished observations).
Preparation of explants of mouse and rat choroid plexus
All of the experiments were performed after protocol
review and approval by local Institutional Animal Care
Committees as indicated below. Although the biopan-
ning protocols used CP from Balb-C mice, we found
that the 3 peptides selected for testing were effective on
mouse and rat CP epithelial cell explants, regardless of
the originating strain, sex and age. Accordingly, adult
wild type donor C/57Bl and Balb-C mice, or alterna-
tively Wistar and Sprague Dawley rats were used as
indicated as the source of CP tissue and brains were
immediately dissected and placed onto wet ice. The CP
were harvested from 4th ventricles by carefully separat-
ing the cerebellum from the brain stem and dissecting
the choroid plexus from the roof of the cerebellum with
tweezers. The lateral ventricle CP were dissected after
removal of the 4th ventricle’s CP by immersing the brain
in PBS and making two parallel sagittal incisions 10 mm
from the midline along the length of the brain to a
depth of 4 mm so as to cut through the corpus callo-
sum. The cortex was then pulled away to the side
exposing the lateral ventricles and choroid plexus. With
a pair of tweezers, each end of the CP was gently pulled
away and placed in RPMI media containing 10% fetal
calf serum (FCS) and 5% normal horse serum (NHS).
Experiments with CP explants were performed immedi-
ately after harvest.
Culture of primary rat choroid plexus (CP) epithelial cells
We evaluated the effects of ligand targeting in vitro
using an immortalized choroid plexus cell line (TRCSFB
cells) developed from transgenic Wistar rats [77].
TRCSFB cells were plated on flasks coated with collagen
type I (BD Biosciences) and cultured in DMEM + Gluta-
MAX (Invitrogen) supplemented with 4.5 g/L glucose,
5 ml Sodium Pyruvate (100 mM, Invitrogen), 5 ml
NEAA (non-essential amino acids, ×100, (Invitrogen), 5
ml Penicillin/Streptomycin (10,000 units/ml Penicillin,
10,000 μg/ml Streptomycin, Invitrogen), and 10% FBS
(Sigma).
Incubation with phage in vitro, ex vivo and in vivo
As indicated in each of the experiments, ligand-targeted
and untargeted phage particles were added to either
TRCSFB cells or to the CP explants and incubated at
37C in 95% CO2 controlled atmosphere. Experiments
with CP explants were not extended beyond 2 hours to
ensure patency of the epithelial cells. At the end of the
indicated incubations, the cells or tissue were rinsed
first in 10 mM PBS containing Ca+2 and Mg+2, and
then washed briefly in either 50 mM Glycine buffer pH
2.8 (cells in culture) or 10 mM PBS Ph 7.4 containing
0.3% Tween 20. The amount of phage bound and inter-
nalized was evaluated by immunohistochemistry.
To evaluate targeting in vivo, peptide-targeted and
untargeted phage were injected icv into mice and rat
brains as specifically indicated. All procedures involving
the use of rats followed strict adherence to Home Office
guidelines (UK), and with approval of the local ethics
committee while all mice i.c.v. injections were approved
by the Institutional Animal Care and Use Committee at
the University of California San Diego. Thirty minutes
prior to receiving surgery, adult male Wistar (Charles
River) rats (200-250 g) received analgesia through a sub-
cutaneous injection of 0.03 mg/kg buprenorphine. The
rats were then anaesthetised using 5% isofluorane, deliv-
ered with O2 at 1.7 L/min through a mask, and full
anaesthesia was maintained throughout the surgery.
During surgery, rats was immobilised in a stereotactic
frame with the head elevated and parallel to the table
surface. A sagittal incision was made along the midline
of the scalp and teased apart to expose the skull. The
landmark at co-ordinates 0/0 that indicate Bregma
crossing the midline was marked using a fine marker
pen. A small hole was drilled in the skull using a micro
drill, 1.5 mm lateral to the midline, 1 mm posterior to
Bregma. The needle of the Hamilton syringe was
inserted 4 mm deep from the brain surface and 20 μl of
phage solution was injected over 30 seconds. The syr-
inge was left in the brain for one minute to prevent
fluid reflux. Once the i.c.v. injection was complete the
syringe was removed and the skin sutured, and the ani-
mal was taken off the anaesthetic and allowed to recover
on a warm fleece bed. At specific times after injection
(24-72 hours), the rats were humanely killed by deliver-
ing rising concentrations of CO2 and immediately
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perfused with 4% paraformaldehyde in PBS, pH 7.4. The
brains were dissected and post-fixed for 4 h at 4C. The
tissues were then cryoprotected by being placing them
in raising concentrations of sucrose (10-30%) in PBS at
4°C. Tissues were embedded in OCT (RA Lamb Labs)
and stored at -80C until required. Twelve micron-thick
coronal midbrain sections were mounted onto positive
charged slides to perform immunohistochemistry.
Immunohistochemistry and detection of internalized
phage
Prior to fixation, CP cells in culture and CP tissue
explants were rinsed in 50 mM Glycine buffer pH 2.8
for 5 min or 10 mM PBS pH 7.4 containing 0.3%
Tween-20 (Sigma), respectively. Cells and tissue samples
were then rinsed in PBS (3X) and fixed for 20 min at
room temperature in 2.2% formaldehyde in 10 mM PBS
pH 7.4 containing 2% glucose and 0.02% sodium azide.
Cells and explants were rinsed once with PBS, permea-
bilized in methanol for 6 min, and washed twice again
with PBS. Immunofluorescence and immunoperoxidase
staining techniques using antibodies to the coat protein
M13 phage were used to detect internalized phage in
either cultured epithelial cells in vitro, CP tissue
explants or midbrain coronal brain sections after ICV
injection of phage particles. To block non-specific stain-
ing, cells and tissue samples were incubated with PBS
containing 1% BSA (Jackson Immuno Research), 0.3%
Tween 20 (Sigma), and 10% NGS (Jackson Immuno
Research) for 20 minutes at room temperature. Excess
blocker solution was drained and samples incubated
with rabbit anti-bacteriophage (1/200, Sigma) for 1 h at
room temperature, rinsed and then incubated with sec-
ondary labelled anti rabbit antibodies. For immunofluor-
escence staining, samples were then incubated for
45 min at room temperature with Alexa594 labelled goat
anti-rabbit antibodies (Invitrogen). After washing with
PBS, cell and tissue samples were mounted using Vecta-
shield mounting medium containing DAPI (Vector
Labs) and visualized under an epifluorescent microscope
and confocal microscopy. In some instances peroxidase
staining was used to evaluate the distribution of phage
particles in the brain after i.c.v. injection. In this
instance, after incubation of the tissues with rabbit anti-
M13 antibodies, tissue sections were rinsed and incu-
bated with biotinylated goat anti-rabbit IgG (Vector) for
45 min at room temperature. The tissue sections were
rinsed in PBS and endogenous peroxidase quenched by
incubating the tissue sections in 0.3% hydrogen peroxide
(30% H2O2, Sigma) for 30 min, washed in PBS, and
incubated with ABC solution (ABC Kit, Vector Labs) for
30 min. Sections were incubated in Diaminobenzidine
(DAB, Vector Labs) for 5-7 min rinsed, dehydrated,
cleared in Histoclear and mounted. Immunostaining was
visualized under bright field microscopy and DIC optics
(Zeiss Axioplan).
Evaluation of targeting specificity
To investigate whether the internalization of peptide-
targeted phage was ligand specific, we performed com-
petition assays using the cognate synthetic peptides
displayed on phage. TRCSFB cells or tissue explants
were incubated for 2 hr at 37C under 5% CO2 with pep-
tide-targeted phage (1012 particles/ml) 10-15 minutes
after having added 200 ng to 1 ug of the cognate
synthetic peptide. Peptides were prepared by solid phase
synthesis in the University of Birmingham Protein Core
Laboratories, evaluated by amino acid analyses and puri-
fied to >95% homogeneity.
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